<DOC>
	<DOC>NCT01086813</DOC>
	<brief_summary>Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly(=65 years) Healthy Volunteers</brief_summary>
	<brief_title>Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043</brief_title>
	<detailed_description>Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly (=65 years) Healthy Volunteers</detailed_description>
	<criteria>Preanaesthesia assessment judged without remarks by the investigator. ASA physical status category 1 to 2 (up to and including 3 depending on applicable patient category) Lack of a normal range of enzyme activity for BuChE Known or suspected history of hypersensitivity to drugs with a similar chemical structure or class to AZD3043 (e.g., emulsionbased products like Diprivan,Intralipid), allergies to soybean or peanut products or any other drugs intended for use during th Prolonged QTcF &gt;450 ms or shortened QTcF &lt;350 ms or family history of long QT syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sedation</keyword>
</DOC>